Effect of Lactobacillus Paracasei PS23 on Improving Aging and Muscle Loss in the Elderly
Launched by CHI-CHANG HUANG · Sep 25, 2023
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Taiwan has become an aging society in recent years. There are important issues to attenuate aging and activate the potential capacity of elderly population. The physical function of middle-aged and older people will degenerate with age and produce age-related diseases. Common symptoms are organ function deterioration, and old age disability caused by malnutrition and muscle loss is also a common care problem. Therefore, how to prevent the complications of muscle loss is one of the important ten years of geriatric research. Although past research has been confirmed, it can improve the debili...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age between 65 and 85 years old
- Exclusion Criteria:
- • Have taken antibiotics within one month or are receiving antibiotic treatment
- • Have used probiotic products in powder, capsule or tablet form within two weeks (except for yogurt, yogurt, Yakut and other related foods)
- • People allergic to lactic acid bacteria products
- • Patients diagnosed with stroke or hypertension (systolic blood pressure greater than 139, diastolic blood pressure greater than 89)
- • Exclusion of limbs and hips that have been replaced with artificial joints
- • Persons with incapacity/insufficient decision-making ability
- • Who has been determines that it is not suitable to participate in the research.
About Chi Chang Huang
Chi-Chang Huang is a dedicated clinical trial sponsor with a robust commitment to advancing healthcare through innovative research. With a focus on developing new therapies and improving patient outcomes, Huang leads initiatives that prioritize scientific rigor and ethical standards. His extensive experience in clinical trial management encompasses various therapeutic areas, fostering collaborations with healthcare professionals, regulatory bodies, and research institutions. Through a patient-centered approach, Chi-Chang Huang aims to bridge the gap between scientific discovery and clinical application, ultimately contributing to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taoyuan, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported